This Competitive Intelligence report about CDK9 and Mcl1 Inhibitors provides a competitor evaluation in the field of inhibitors of CDK9 and Mcl-1 as of March 2018.
Cyclin-dependent kinase 9 (CDK9) regulates elongation of transcription through phosphorylation of RNA polymerase II (pSer2-RNAPII), and its short-term inhibition results in the selective downregulation of genes with short-lived transcripts and labile proteins - including the „pro-survival" protein Mcl1.
Myeloid Cell Leukaemia-1 (Mcl-1), an anti-apoptotic member of the Bcl-2 protein family, has emerged as an especially attractive target for the development of next generation antineoplastics owing to its direct involvement in tumor genesis as well as its role in the resistance of many cancers to current anti-cancer therapies.
The report includes a compilation of currently active projects in research and development of small molecule and biologic inhibitors of CDK9 or Mcl-1. In addition, the report lists company- and institution-specific R&D pipelines of CDK9 and Mcl-1 inhibitors.
Competitor projects are listed in a tabular format providing information on:
- Drug Codes
- Target/Mechanism of Action
- Class of Compound
- Product Category
- R&D Stage
- Additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1 CDK9 and Mcl-1 Inhibitors
- Cyclin-Dependent Kinase 9 (CDK9) Inhibitors
- Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors
2 Corporate CDK9 & Mcl-1 Inhibitor R&D Pipelines